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Summary: Topical 2% mupirocin ointment eradicated chronic Staphylococ- 
cus aureus nasal carriage immediately post-therapy in 17 (77%) of 22 
haemodialysis patients. Mean time to recurrence was 3.8 weeks. Similar pre- 
therapy and post-therapy phage types occurred in 12 (71%) of 17 patients. 
Staphylococcus aureus infections developed in none of 17 successfully treated 
patients, two of five treatment failures (P = 0.05), and 10 of 46 untreated 
patients studied concurrently (P = 0.03). 
Keywords: Mupirocin; haemodialysis; Staphylococcus aureus; nasal coloniza- 
tion. 
Introduction 
Infection is the second leading cause of morbidity and mortality in 
haemodialysis patients. Staphylococcus auyeus is the most significant 
pathogen, accounting for 70-96% of bacterial infections.‘-3 In a prospective 
study, Yu et aL4 showed a decreased incidence of S. aureus infections if 
5’. aureus nasal carriage was eliminated. Until recently, only systemic 
therapy with either rifampicin or clindamycin reliably eradicated S. aureus 
nasal carriage in haemodialysis patients.’ These drugs are expensive and 
may be associated with significant toxicity. Topical gentamicin, 
vancomycin, bacitracin and oral cloxacillin or tetracycline have interrupted 
S. aureus nasal carriage for less than 2 weeks before relapse occurred.’ 
Mupirocin is a new topical antimicrobial which has been reported to 
effectively eradicate S. aureus nasal carriage in some patient populations6a7 
including haemodialysis patients.8 Mupirocin reversibly binds to bacterial 
isoleucyl-transfer RNA synthetase preventing protein and RNA 
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synthesis.“” It is active against most Gram-positive skin pathogens, 
although low and high level resistance has been reported.“-13 
We undertook this pilot study to determine: (a) the efficacy of mupirocin 
in eliminating nasal carriage in a dialysis population and (b) the length of 
time patients remained free of nasal S. aureu~ carriage following treatment. 
Methods 
Population and design 
All patients attending an outpatient chronic haemodialysis unit were 
eligible for enrolment. Sixty-eight patients were screened for the presence 
of S. aUYeUs nasal carriage. Patients with two consecutive nasal swabs, taken 
at least one week apart, positive for S. aweus, were considered to be chronic 
S. ~UY~US carriers and enrolled after obtaining informed consent. No subject 
was known to be hypersensitive to mupirocin. 
Patients applied 2% mupirocin ointment in a paraffin/lanolin base three 
times daily for 5 days to the internal, anterior medial septa (Little’s area) of 
both nostrils following directions provided by the study nurse. Each patient 
recorded drug administration and adverse reactions. The study nurse 
reviewed patient diaries and discussed any adverse drug reactions with each 
patient. Surveillance of the haemodialysis unit for S. ~UY~US nasal carriage 
was discontinued after study enrolment was completed. A concurrent 
prospective study documented infectious morbidity and mortality of all 
patients in the unit throughout the surveillance and study period. 
Microbiology 
Nasal swabs for 5’. UUY~US carriage were taken at pre-enrolment, at the first 
dialysis visit following completion of therapy (end of therapy), weekly for 4 
weeks, then monthly for 2 months. Specimens were transported to the 
laboratory in Amies transport media, inoculated onto 5% sheep blood agar 
and 10% mannitol salt agar plates, and incubated aerobically at 37°C for 48 
hours. Gram-positive coagulase positive cocci isolated from the blood agar 
plate were identified as S. uureus. Oxacillin disc (1 mg, BDL) sensitivities 
were performed on all S. aUreUs isolates. Isolates growing within 13 mm of 
the oxacillin disc were inoculated onto Mueller Hinton plates containing 
6 mg 1-l oxacillin to verify methicillin resistance. Mupirocin susceptibility 
was determined by Kirby-Bauer agar disc method (1 I-18 disc). 
Staphylococcus aweus isolates were phage typed by the Laboratory Center 
for Disease Control, Ottawa, Canada. 
Dejkitions and data analysis 
Patients were considered cured if S. aweus was not isolated in any 
post-therapy cultures. If S. aweus was isolated on the first nasal swab 
obtained after completion of therapy, patients were designated failures. 
Patients relapsed when the S. aweus strain isolated post-therapy did not 
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differ by more than two phage types from the pre-therapy isolate and were 
considered recolonized if the post-therapy strain differed by more than two 
phage types. Patients with non-typable strains isolated both pre-therapy 
and post-therapy were considered relapses. Analysis was performed using 
the X2-square test. 
This phase two trial was approved by the University of Manitoba, 
Faculty Committee on Human Subjects in Research and the Health 
Sciences Centre Research Committee. 
Results 
Twenty-two (32%) of 68 patients in the haemodialysis unit were identified 
as S. aweus nasal carriers during the 70-day surveillance study which 
preceded the mupirocin trial. All 22 patients were enrolled in the trial. 
Twelve different phage types were identified in these 22 patients. Seventeen 
(77%) patients were culture negative at the end of therapy. The mean time 
to recurrence for those negative at the end of therapy was 3.8 weeks. Ten 
(46%) patients remained culture negative 4 weeks post-therapy, seven 
(32%) at 2 months, and five (23%) at 3 months. The positive nasal carriers 
at 3 months included five (23% of total) failures of therapy, seven (32%) 
relapses and five (23%) recolonized. Thus, similar pre- and post-therapy 
phage types occurred in 12 of 17 (71%) patients not cured. All pre- and 
post-therapy S. aweus isolates were susceptible to mupirocin. The single 
subject with a pre-treatment methicillin-resistant S. aweus isolated was a 
treatment failure. 
Therapy was well tolerated. Three (13%) of 22 patients complained of 
mild nasal itching. Although one of these patients missed three doses, the 
course of therapy was subsequently completed. An additional patient 
missed four doses for unknown reasons. Staphylococcus aweus nasal 
carriage recurred in both of these patients, one as a relapse, and one 
recolonized. 
None of the 17 patients who were culture negative at completion of 
therapy developed S. aweus infections during the three months follow-up. 
Staphylococcus aureus cellulitis was observed, however, in two (40%) of five 
patients who failed therapy (P = 0.05). Ten (22%) of 46 patients not 
enrolled in the study but followed concurrently had S. aweus infection 
(P = O-03). Th ese 10 infections included three fistula site infections, three 
episodes of sepsis, two pneumonias, and one each of cellulitis and soft tissue 
infection. 
Discussion 
These observations contrast with the report of Chow & Yu’ who found less 
than 25% of patients using topical agents such as gentamicin, vancomycin 
or bacitracin remained culture negative 3-14 days after completing 
treatment. Our results are, however, similar to the observed response to 
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systemic therapy. Yu et al. 4 found 75% of patients remained culture 
negative after combined therapy with oral rifampicin and topical bacitracin 
1 month after therapy, but most patients had positive nasal cultures for 
S. aweus by 3 months after therapy. Boelaert et aZ.’ have also recently 
reported that continuously administered mupirocin eradicated S. aweus 
nasal carriage in haemodialysis patients and was associated with a decreased 
incidence of S. aweus infections. Although they reported no mupirocin 
resistance, the continual administration of drugs would likely increase the 
potential for resistance to develop. Our study suggests that the intermittent 
use of mupirocin may also be effective in eradicating S. aweus carriage in 
haemodialysis and is associated with a significant decrease in S. aweus 
infections. 
We observed a higher relapse rate and lower recolonization rate than was 
observed in a study using a S-day course of mupirocin to eradicate chronic 
S. aweus nasal carriage in a group of 32 healthy subjects. Casewell & Hill6 
found 10 (71%) of 14 patients recolonized and four (29%) relapsed during 
22 weeks of follow-up. These authors postulated that patients who relapsed 
were colonized with S. aweus at other sites. This hypothesis may explain 
why our patients had a higher rate of relapse. Compared to healthy controls, 
haemodialysis patients have twice the rate of S. aweus skin colonization.14-16 
Staphylococcus aweus skin colonization has recently been correlated with 
personal hygiene in haemodialysis patients.r7 As this study did not include 
any evaluation of personal hygiene, it is not known whether the patients who 
failed had poorer personal hygiene. The level of personal hygiene may be 
relevant to the two patients who developed S. aweus infections after failing 
to eliminate S. aweus nasal carriage. 
This preliminary information suggests that a prospective, randomized 
placebo-controlled trial to determine efficacy and cost benefit of mupirocin 
in this population is warranted. 
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